Pompe Disease Market Set for Robust Growth Through 2034

Strategic Insights -

The Pompe disease treatment market is experiencing significant expansion driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players. The market is dominated by the United States, which captured about 70% of the overall market share in 2024. DelveInsight's report delivers an in-depth understanding of the Pompe disease treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and Pompe disease market forecasts through 2034, providing crucial insights for stakeholders in the Pompe therapeutic area.

Key Takeaways:

  • The Pompe disease market is driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Sanofi, Genzyme, Amicus Therapeutics, GeneCradle Therapeutics, Astellas Gene Therapies, Spark Therapeutics, Aro Biotherapeutics, Maze Therapeutics, Valerion Therapeutics, Actus Therapeutics, Roche, and Lacerta Therapeutics, among others.
  • The United States captured about 70% of the overall market share in 2024, significantly outpacing those of the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
  • Within Europe, Germany led among the EU4 and the UK, followed by France, while Spain had the smallest market size in 2024.
  • The epidemiological analysis reveals that there were approximately 13K prevalent cases of Pompe disease across the 7MM in 2024, with numbers expected to rise by 2034.
  • The EU4 (Germany, Spain, Italy, France) and the UK together accounted for about 25% of these cases.
  • The United States had around 8.6K diagnosed cases in 2024, with a striking 98% occurring in adults.
  • Infantile-onset Pompe disease, though less common, is associated with high mortality in the first months of life due to severe muscle weakness and respiratory complications, causing significant psychological distress for affected families.
  • In 2024, about 80% of infantile-onset Pompe disease cases in the US were CRIM-positive, a phenotype marked by residual enzyme activity that can influence both disease progression and treatment response.
  • Sanofi's MYOZYME (alglucosidase alfa) and LUMIZYME (alglucosidase alfa) are established enzyme replacement therapies that have been cornerstones of treatment for over a decade.
  • A significant milestone occurred with the FDA approval of Sanofi's NEXVIAZYME (avalglucosidase alfa-ngpt) in 2021 for patients aged one and older with late-onset Pompe disease.
  • Amicus Therapeutics' two-component therapy was approved in September 2023 for adults with LOPD who weigh at least 40 kg and are not responding adequately to existing enzyme replacement therapies.
  • The Pompe disease therapies pipeline is promising, targeting novel treatment approaches, including gene therapy and substrate reduction therapies.
  • GeneCradle Therapeutics' GC301 is showing potential for enzyme replacement therapy discontinuation and motor ability improvement.
  • Maze Therapeutics' MZE001 is progressing through Phase I trials, aiming to reduce glycogen buildup in Pompe disease patients.

Statistics:

  • The Pompe disease market is expected to grow significantly through 2034, driven by breakthrough therapies and expanding pipeline.
  • There were approximately 13K prevalent cases of Pompe disease across the 7MM in 2024.
  • The EU4 (Germany, Spain, Italy, France) and the UK together accounted for about 25% of these cases.
  • The United States had around 8.6K diagnosed cases in 2024, with a striking 98% occurring in adults.
  • Infantile-onset Pompe disease is associated with high mortality in the first months of life due to severe muscle weakness and respiratory complications.
  • About 80% of infantile-onset Pompe disease cases in the US were CRIM-positive in 2024.

Sources:

  • DelveInsight's "Pompe Disease Market Insight, Epidemiology And Market Forecast - 2034" report
  • M2 PRESSWIRE-June 17, 2025-: Pompe Disease Market Set for Robust Growth Through 2034, Driven by Breakthrough Therapies and Expanding Pipeline
  • www.abnewswire.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.m2.co.uk on the world wide web. Inquiries to info@m2.co.uk))